Nezam El-Tayebat Fact CheckA scientific assessment of the “نظام الطيبات” nutrition system
Choose country
Choose language: English

Mostly true Scientifically well supported Certainty of evidence: moderate provisional C-PPI-03

Long-term acid suppression is linked to vitamin B12 deficiency and low magnesium.

In short: Correct: long-term acid suppression is associated with vitamin B12 deficiency, low magnesium and iron deficiency, with dose-response; the absolute risk is modest and can be monitored.
Conclusion: Correct as an association with long-term use; the risk is modest and manageable.
  1. Original statement
  2. Scientific assessment
  3. Scientific evidence in detail
  4. In plain language
  5. Studies on this claim
  6. Regional context
  7. What applies in my country?
  8. References

Original statement

حمض المعدة ليس عدوّاً يجب قمعه، بل أداة أساسية للهضم وقتل الميكروبات وامتصاص الحديد وفيتامين ب12 والكالسيوم والمغنيزيوم. تثبيطه لفترات طويلة بـ PPIs (أوميبرازول، نكسيم، كونترلوك) أو مثبطات H2 ينقلب على الجسم: مرض كلوي مزمن، فرط نمو بكتيري، عدوى مطثية عسيرة، التهاب رئوي، نقص B12 والمغنيزيوم، كسور ورك، تغيّر الميكروبيوم، وزيادة الوفيات. والأخطر أنّ الجسم يدمن الدواء عبر فرط الإفراز الارتدادي بعد الإيقاف، فيتحوّل الاستخدام القصير إلى اعتماد مزمن.

not verbatim – paraphrase. Translation by the project; the Arabic wording is authoritative.

Translation

Long-term acid suppression is linked to vitamin B12 deficiency and low magnesium.

Origin

Source status
Archive editors
Attribution
Archive editors (eltayebat.com); not verified as Elawady's own words
Origin
https://eltayebat.com/rule/acid-blockers/
Attribution uncertainty
Written by the archive operators; study selection is the archive's, not necessarily Elawady's.
Claimed mechanism

Acid is needed to release B12 from food proteins; mechanism of PPI-related hypomagnesaemia is thought to involve intestinal absorption.

Claimed health effect

Vitamin B12 deficiency, hypomagnesaemia.

Population concerned

Long-term PPI (and H2RA) users.

Geographic restriction by Elawady

none found

Scientific assessment

Mostly true – Correct at its core, but with limitations or minor inaccuracies.

Certainty of evidence: moderate – Further research may still affect the assessment.

1. What was claimed?

Long-term acid suppression causes B12 and magnesium deficiency.

2. What is demonstrably correct?

Association is documented: ≥2 years of PPI supply OR 1.65 (1.58–1.73) for B12 deficiency, with dose-response; PPI use OR 2.00 (1.36–2.93) for hypomagnesaemia, stronger after prolonged use. A physiological mechanism exists.

3. What is wrong or exaggerated?

The archive's 'raised risk by 65%' wording is causal; the design is case-control. Absolute effects on serum magnesium in the general population were small (−0.022 mEq/L).

4. What remains unclear?

How many long-term users develop clinically relevant deficiency is not well quantified.

5. Which studies support it?

A-PPI-09, A-PPI-10.

6. Which studies contradict it?

AGA 2017 (I-PPI-03) advises against routine screening or extra supplementation beyond the RDA for all long-term users – i.e., the risk is considered small at population level.

7. What applies to Germany and Europe?

PPIs are among the most widely prescribed drugs in Germany and Europe; several (e.g. pantoprazole, omeprazole) are sold over the counter in small packs for short-term use. European data (Stockholm, UK GPRD/CPRD, Rotterdam) are among the cited cohorts, so the observational findings apply to European users with the same confounding limits.

8. What is known about Egypt?

Elawady describes PPIs (Controloc, Nexium) as widely used and sold without prescription in Egypt. No Egypt-specific outcome data were reviewed. The biology and trial results are not expected to differ by country; H. pylori infection, which is common in many countries, is an additional reason why acid-suppression and eradication therapy are prescribed.

9. What practical conclusion is appropriate?

For long-term PPI users with symptoms (e.g. neuropathy, anaemia, cramps) or extra risk factors, checking B12 or magnesium is reasonable; this is a monitoring issue, not a reason for a blanket ban.

Assessment details

Rationale for certainty of evidence

Large case-control (Kaiser, 25,956 cases) and cohort (Rotterdam) studies with dose-response; plausible mechanism. Observational design; the AGA does not recommend routine monitoring or extra supplementation for all users.

Source quality

Correctly reported observational studies.

Regional transferability

High.

Individual exceptions

People on loop diuretics or with low intake are at higher risk (Rotterdam: OR 7.22 with loop diuretics, very few cases).

Regional scope of the claim
general (biological/medical)
Last reviewed
26 October 2026 provisional

Scientific evidence in detail

Scientifically well supported – The claim agrees with consistent, high-quality evidence.

Research question: Is long-term acid suppression associated with vitamin B12 deficiency and low magnesium?

Research question in detail (PECO)
Population
Adult long-term PPI users
Intervention or exposure
PPI >=2 years
Comparison
Non-use
Geographic scope
universal pharmacology
Outcomes
  • B12 deficiency
  • Hypomagnesaemia
  • Iron deficiency

Study results as reported by the authors. Our assessment follows below.

What speaks for the claim?

What speaks against the claim?

  • AGA advice on long-term PPIs

    Freedberg DE et al.. Gastroenterology 2017 · PMID 28257716 · DOI 10.1053/j.gastro.2017.01.031 Guideline / position statementabstract checked

    AGA 2017 does not recommend routine screening or extra supplementation for all long-term users.

    Actual result
    Best practice advice (packet)
    Methodological quality
    guideline
    Relevance
    indirect: risk considered small
    Limitations
    Expert review

    Original publication

What does the overall evidence say?

Editorial assessment based on the studies above – not itself a study result.

Which position is better supported?

The association is real, dose-dependent and biologically plausible; absolute risk is modest.

Why some studies weigh more

Large consistent observational studies with dose-response and mechanism.

Is a causal relationship established? Probable Dose-response, reversibility and mechanism support causality.

Remaining uncertainty

Clinical relevance per user.

Justified conclusion

Correct as an association with long-term use.

Does this depend on the country?
General biological effects
Pharmacology of PPIs is the same in Egypt and Europe.
Eating habits
Not decisive.
Origin of the food
Not relevant.
Contaminants
Not relevant (except ranitidine NDMA impurities, C-PPI-08).
National production conditions
Generic products are used in both regions; no evidence of different pharmacological effects.
Legal rules
PPIs are partly available without prescription in Egypt and (small packs, short-term) in the EU; prescribing practices differ.
Actual monitoring data
No Egyptian outcome data identified; one Egypt/Iraq pharmacist survey (I-PPI-120).

A regional difference that changes the conclusion is not supported by robust data.

Statistical re-check
  • Crude vs adjusted OR; share of cases exposed – Crude OR 3.61 vs adjusted 2.49; only 3.0% of iron-deficiency cases had >=2 y PPI supply recalculated
Certainty of the overall evidence (GRADE, simplified)
Main outcome
B12/magnesium/iron deficiency with long-term PPI
Starting level
low (observational studies)
Reasons for upgrading
  • dose-response
  • plausible mechanism
Result
moderate

Simplified assessment by a single reviewer, following the GRADE approach; not a formal GRADE panel. GRADE rates the body of evidence for one outcome, not individual studies.

Search strategy

Documented literature searches for this review (search strings in the original database syntax).

DatabaseDateSearchLooking forHitsIncluded
Europe PMC26 October 2026TITLE:("proton pump inhibitor*" OR "acid suppress*") AND TITLE:(hypomagnes* OR magnesium OR "vitamin B12" OR cobalamin OR "iron deficiency") AND ("meta-analysis" OR "systematic review")both directions13
Europe PMC26 October 2026AUTH:"Lam JR" AND TITLE:"iron deficiency"supporting evidence1

Open questions

Proportion of users with clinically relevant deficiency.

How deeply was this checked?

4 linked studies: 0 checked in full text (0 of them with a structured risk-of-bias assessment), 4 on the basis of the abstract, 0 bibliographically only. No formal assessment with two independent reviewers and no independent human expert review has taken place yet.

Last scientific review: 26 October 2026

History of the verdict
  1. 25 October 2026 · Phase 1 · Initial assessment: Mostly true (moderate)
  2. 26 October 2026 · Phase 4 (systematic evidence review) · Re-examined with extended evidence; verdict unchanged: Mostly true (moderate)
    Iron data strengthen the nutrient-specific picture; verdict unchanged.
    New sources: I-PPI-116

In plain language

Stomach acid helps to free vitamin B12 from food. People who take acid blockers for years are more often found to have low B12, and sometimes low magnesium. The risk is real but modest, and it can be checked with a blood test if symptoms appear.

Studies on this claim

Studies supporting the claim (3)

  • Acid blockers and low vitamin B12

    Lam JR et al.. JAMA 2013 · PMID 24327038 · DOI 10.1001/jama.2013.280490
    Case-control studycited by the Tayebat archiveabstract checked★ key study

    Two or more years of PPI supply was associated with 65% higher odds of B12 deficiency.

    Does the study support the specific claim? Yes · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    B12 deficiency association.

    How was the study done?

    Case-control in a health system.

    How many people, animals or samples were studied?

    210,155 patients.

    What was actually found?

    Higher odds with PPI and H2RA.

    How large was the observed effect?

    OR 1.65 / 1.25.

    What do the results mean in everyday life?

    Long-term users may need B12 checks if symptoms.

    What are the study's limitations?

    Detection bias.

    What does it say about Elawady's specific claim?

    Supports C-PPI-03.

    Do the results apply to Germany and Europe?

    Applicable.

    What can explicitly not be concluded from this study?

    Exact causal size.

    Scientific details →

  • PPIs and low magnesium (Rotterdam)

    Kieboom BC et al.. Am J Kidney Dis 2015 · PMID 26123862 · DOI 10.1053/j.ajkd.2015.05.012
    Cross-sectional studycited by the Tayebat archiveabstract checked

    PPI users had twice the odds of low magnesium, especially with long use and loop diuretics.

    Does the study support the specific claim? Yes · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Mg and PPIs.

    How was the study done?

    Population cohort.

    How many people, animals or samples were studied?

    9,818.

    What was actually found?

    Higher odds of low Mg.

    How large was the observed effect?

    OR 2.00.

    What do the results mean in everyday life?

    Check Mg with diuretics.

    What are the study's limitations?

    Single measurement.

    What does it say about Elawady's specific claim?

    Supports.

    Do the results apply to Germany and Europe?

    Dutch data.

    What can explicitly not be concluded from this study?

    Causation.

    Scientific details →

  • Long-term acid blockers linked to iron deficiency

    Lam JR et al.. Gastroenterology 2017 · PMID 27890768 · DOI 10.1053/j.gastro.2016.11.023
    Case-control studyindependent cross-checkabstract checked★ key study

    People who took PPIs for 2 years or more had about 2.5 times the odds of iron deficiency, more with higher doses.

    Iron deficiency OR 2.49 with >=2 y PPI, dose-response

    Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Check acid suppression and iron deficiency.

    How was the study done?

    Case-control study.

    How many people, animals or samples were studied?

    77,046 cases, 389,314 controls.

    What was actually found?

    OR 2.49 for >=2 y PPI; dose-response; reversible.

    How large was the observed effect?

    2.49 (2.35-2.64).

    What do the results mean in everyday life?

    Long-term users may need iron checked if symptomatic.

    What are the study's limitations?

    Observational.

    What does it say about Elawady's specific claim?

    Supports nutrient-specific effects, not 'nothing is absorbed'.

    Do the results apply to Germany and Europe?

    Applicable.

    What can explicitly not be concluded from this study?

    Cannot prove causation in every user.

    Scientific details →

Studies contradicting or limiting the claim (0)

No studies in this group.

Studies with mixed or unclear results (1)

  • AGA advice on long-term PPIs

    Freedberg DE et al.. Gastroenterology 2017 · PMID 28257716 · DOI 10.1053/j.gastro.2017.01.031
    Guideline / position statementindependent cross-checkabstract checked

    PPIs are justified for defined indications; risks do not require routine monitoring.

    Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Risk–benefit guidance.

    How was the study done?

    Expert review.

    What was actually found?

    10 best practice statements.

    What do the results mean in everyday life?

    Use for real indications at lowest dose.

    What are the study's limitations?

    Expert opinion.

    What does it say about Elawady's specific claim?

    Mixed: supports indication-based use.

    Do the results apply to Germany and Europe?

    Applicable.

    Scientific details →

Regional context

Germany / EU

PPIs are among the most widely prescribed drugs in Germany and Europe; several (e.g. pantoprazole, omeprazole) are sold over the counter in small packs for short-term use. European data (Stockholm, UK GPRD/CPRD, Rotterdam) are among the cited cohorts, so the observational findings apply to European users with the same confounding limits.

Egypt

Elawady describes PPIs (Controloc, Nexium) as widely used and sold without prescription in Egypt. No Egypt-specific outcome data were reviewed. The biology and trial results are not expected to differ by country; H. pylori infection, which is common in many countries, is an additional reason why acid-suppression and eradication therapy are prescribed.

What applies in my country?

General scientific assessment

Mostly true Correct as an association with long-term use; the risk is modest and manageable.

This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.

References

  1. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency.. Lam JR et al.. JAMA 2013 · PMID 24327038 · DOI 10.1001/jama.2013.280490
  2. Proton pump inhibitors and hypomagnesemia in the general population: a population-based cohort study.. Kieboom BC et al.. Am J Kidney Dis 2015 · PMID 26123862 · DOI 10.1053/j.ajkd.2015.05.012
  3. Proton Pump Inhibitor and Histamine-2 Receptor Antagonist Use and Iron Deficiency.. Lam JR et al.. Gastroenterology 2017 · PMID 27890768 · DOI 10.1053/j.gastro.2016.11.023
  4. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.. Freedberg DE et al.. Gastroenterology 2017 · PMID 28257716 · DOI 10.1053/j.gastro.2017.01.031

← Back to overview